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Abstract
Background: Insulin is a critical component of metabolic control, and as such, insulin gene expression has been the focus of
extensive study. DNA sequences that regulate transcription of the insulin gene and the majority of regulatory factors have
already been identified. However, only recently have other components of insulin gene expression been investigated, and in
this study we examine the role of DNA methylation in the regulation of mouse and human insulin gene expression.
Methodology/Principal Findings: Genomic DNA samples from several tissues were bisulfite-treated and sequenced which
revealed that cytosine-guanosine dinucleotide (CpG) sites in both the mouse Ins2 and human INS promoters are uniquely
demethylated in insulin-producing pancreatic beta cells. Methylation of these CpG sites suppressed insulin promoter-driven
reporter gene activity by almost 90% and specific methylation of the CpG site in the cAMP responsive element (CRE) in the
promoter alone suppressed insulin promoter activity by 50%. Methylation did not directly inhibit factor binding to the CRE
in vitro, but inhibited ATF2 and CREB binding in vivo and conversely increased the binding of methyl CpG binding protein 2
(MeCP2). Examination of the Ins2 gene in mouse embryonic stem cell cultures revealed that it is fully methylated and
becomes demethylated as the cells differentiate into insulin-expressing cells in vitro.
Conclusions/Significance: Our findings suggest that insulin promoter CpG demethylation may play a crucial role in beta cell
maturation and tissue-specific insulin gene expression.
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Introduction
Insulin is a master regulator of metabolic homeostasis and it is
secretedfrompancreaticbetacellsinresponsetonutrientstimulation.
Insulin gene expression begins early in the embryonic development of
the pancreas and remains tightly-regulated throughout adult life. The
mouse genome contains two insulin genes, Ins1 (GeneID: 16333) and
Ins2 (GeneID: 16334). The Ins2 gene has greater structural and
functional similarity to other mammalian insulin genes, whereas Ins1
is considered to be a functional retroposon since it possesses only one
of the two introns present in Ins2 and other mammalian insulin genes
[1]. Mouse Ins2, but not Ins1, is expressed in the thymus [2], yolk sac
[3], fetal liver [4], and brain [5] as well as the pancreas, similar to the
human gene. Additionally, both Ins2 and the human INS (GeneID:
3630) gene, but not Ins1, are paternally imprinted in the yolk sac [6]
in association with the H19/Igf2 imprint control region [7,8], but
exhibit biallelic expression in the adult pancreas [9]. Since imprinting
of this region is associated with differential DNA methylation patterns
[10,11], we hypothesized that insulin gene expression may be
regulated by DNA methylation.
Mammalian gene promoters contain cytosine-guanosine dinucle-
otide (CpG) sites which play a pivotal role in the control of gene
expression [12,13]. Methylation of the cytosine residues regulates
transcription directly by inhibiting the binding of specific transcrip-
tion factors, and indirectly by recruiting methyl-CpG-binding
proteins and their associated repressive chromatin-remodeling
activities [14]. These epigenetic alterations are responsible for
modulation of developmentally-regulated and tissue-specific gene
expression [15]. DNA sequences that regulate expression of insulin
gene are located within approximately 400 nucleotides upstream of
the transcription start site [16] and direct both tissue-specific and
metabolic-responsive transcription of the insulin gene. Adjacent to
the promoter is a microsatellite variable number tandem repeat
(VNTR) region which is also important for insulin gene expression
and variability in this region is associated with both type 1 (class I
VNTR) and type 2 (class III VNTR) diabetes mellitus [17]. The
pathophysiology of type 1 diabetes (T1DM) is the result of the
destruction of the insulin-producing beta cells, and a promising
treatment paradigm for T1DM is replacement of the missing beta
cells with insulin-producing cells derived from embryonic or other
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develop methods to produce beta cells in vitro, however as yet there
are no reports demonstrating fully functional cells appropriate for cell
replacement therapy. A major hurdle has been achieving normal
levels of insulin gene expression.
Although much is known about the control of insulin gene
expression, DNA methylation of the insulin promoter and its
relationship to gene expression has not been investigated. To
understand the role of epigenetic regulation in beta cells, we
examined the DNA methylation pattern of the insulin gene in
human and mouse beta and non-beta cells and in embryonic stem
cells as they differentiate into insulin-expressing cells.
Results
Beta cell-specific demethylation of the insulin gene
Examination of the mouse Ins2 promoter revealed three CpG
dinucleotide sequences located at positions 2414, 2182, and
2171 bp relative to the transcription start site (Figs. 1A and 2A).
To test whether these CpG sites have a specific methylation
pattern in pancreatic beta cells, we compared the insulin promoter
CpG methylation pattern in pancreatic beta cells with various
other tissues and with the NIT-1 mouse insulinoma cell line. A
portion of the isolated beta cells were immunostained with insulin
and glucagon antibodies which showed that more than 70% of the
cells were positive for insulin (data not shown). Genomic DNA
samples from various mouse tissues, including pancreatic islets,
were bisulfite-treated and analyzed by methylation-specific PCR
(Table 1) followed by sequencing. The sequencing data revealed
that the three CpG sites in the Ins2 promoter are uniquely
unmethylated in pancreatic beta cells and in the insulin-producing
NIT-1 beta cell line [18] but predominantly methylated in other
tissues (Fig. 1A).
There are nine CpG sequences in the human insulin promoter
(2385 to 0 bp) located at positions 2357, 2345, 2234, 2206,
2180, 2135, 2102, 269 and 219 bp relative to the transcription
start site (Fig. 1B). To map the tissue-specific methylation pattern
of the human insulin gene, purified human islets were dissociated
and the beta cell fraction was separated from non-beta cells using
Newport Green FACS sorting [19]. The enriched beta cell
fraction was 70% insulin positive (data not shown) by immuno-
staining. We compared the methylation pattern of the human INS
gene promoter in the beta cell fraction with pancreatic tissue
leftover from islet isolation, which is mostly pancreatic acinar cells
and contains less than 1% beta cells [20]. As shown in Figure 1B,
the insulin promoter in the insulin-producing human beta cell
fraction is unmethylated, but it is predominantly methylated in the
beta cell depleted fraction.
These results demonstrate that the adult human and mouse
insulin gene promoters exhibit a tissue-specific pattern of DNA
methylation.
Methylation suppresses insulin gene expression
Next, we tested whether methylation affects expression from the
insulin gene promoter. A reporter gene construct was made by
inserting the human INS promoter into a luciferase expression
plasmid (pGL4.10INS421bp; Fig. 2A). Additionally, two mouse
Ins2 luciferase reporter constructs were made, one
(pGL4.10Ins2500bp) using Ins2 promoter sequences from 2480
to +15 bp containing all three CpG sites, and the other
(pGL4.10Ins2MP) using Ins2 promoter sequences from 2169 to
+15 bp which does not contain any CpG sites (Fig. 2A). Each
promoter fragment was mock-methylated or methylated with
M.SssI CpG methyltransferase prior to insertion into the pGL4.10
luciferase expression plasmid (so that only the promoter fragments
were methylated) and then used to transfect mouse NIT-1 cells,
which exhibit both basal and stimulated insulin gene expression.
As shown in Figure 2B, methylation of the human INS promoter
suppressed reporter gene expression in NIT-1 cells about eighty-
five percent (1.0060.13 vs. 0.15060.02 RLU; p,0.001). Simi-
larly, CpG methylation significantly suppressed expression from
the mouse Ins2 promoter-driven luciferase reporter construct
(Fig. 2C; 1.0060.10 vs. .21260.15 RLU; p,0.001). By contrast,
the minimal Ins2 promoter, pGL4.10Ins2MP, which lacks the
CpG sites, was not affected by methyltransferase treatment
Figure 1. Tissue-specific methylation of the mouse Ins2 and
human INS promoters. (A) Genomic DNA samples from mouse
muscle, liver, kidney, blood, brain, spleen, whole pancreas, partially
purified pancreatic beta cells (,70%), and the mouse NIT-1 beta cell
line were analyzed for tissue specific methylation patterns of the mouse
Ins2 promoter (position 2480 to +15 bp) which contains three potential
methylation sites. (B) Genomic DNA samples obtained from human
beta cells (‘‘Islet cell fraction’’; ,70% islet cells) and from human
pancreatic exocrine tissue (‘‘Non-islet fraction’’; ,1% islet cells) were
analyzed for methylation of the insulin promoter (2385 – +24 bp),
which contains nine CpG sites. Note that 7 of 24 clones (29%) of the
clones in the beta cell population exhibited some CpG methylation,
consistent with the percentage of non-beta cell contamination.
doi:10.1371/journal.pone.0006953.g001
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total activity of the minimal promoter was approximately thirty-
fold lower than the full-length promoter.
Glucose is the major nutrient regulator of pancreatic beta cell
function and coordinately regulates insulin gene transcription,
with multiple elements of the promoter involved in glucose
responsiveness [21,22]. The A3, E1, and C1 regions are the major
glucose-responsive transcription control elements of the insulin
gene and these elements are conserved in the Ins2 promoter region
[23,24]. Of the three CpG sites, the second CpG site at 2182 bp
of insulin promoter is part of the cyclic adenosine monophosphate
(cAMP) responsive element (CRE), which is conserved through
many species and is required for maximal insulin gene expression
[16]. Forskolin increases intracellular cAMP levels in the beta cell
and activates kinases that phosphorylate CRE binding proteins
which stimulate CRE-dependent transcription [25]. We therefore
tested the effects of a combination of high glucose and forskolin
stimulation in reporter assays using methylated or mock-
methylated pGL4.10Ins2500bp. Glucose and forskolin treatment
significantly stimulated the mock-methylated reporter (Fig. 2C
black bars; 1.0060.10 vs. 1.6560.10, p,0.0001), however did not
stimulate the methylated reporter (Fig. 2C white bars; 0.2160.04
vs. 0.3560.15, p=0.385), nor the minimal Ins2 promoter,
pGL4.10Ins2MP (Fig. 2D black bars; 1.0060.31 vs. 1.0160.16,
p=0.986). These results indicate that CpG sites and their
demethylation status are important for both basal and stimulated
insulin gene expression.
To assess the importance of the individual methylation events
on insulin gene expression, reporter plasmids were made in which
each CpG site was methylated individually, and then tested for the
effects on gene expression. Of the three sites, only methylation of
the CpG site within the CRE (2182) was able to independently
suppress insulin promoter activity, and only by about 50% (Fig. 2E;
1.0060.08 vs. 0.5660.05, p,0.0001). Methylation of the
proximal site (2171) had no effect on gene expression, while
methylation of the distal site (2414) paradoxically increased
Figure 2. Methylation suppresses the activity of both the mouse and human insulin gene promoters. (A) A diagram of the three
luciferase reporter plasmids used to test the effect of methylation on insulin promoter activity. PGL4.10Ins2500bp contains bases 2480 to +15 (three
CpG sites) of the Ins2 gene, pGL4.10Ins2MP contains bases 2169– +15 bp (no CpG sites), and, pGL4.10INS421bp contains bases 2385 to +24 of the
human INS gene (nine CpG sites). The positions of CpG dinucleotides are represented with ‘‘lollipop’’ markers and the positions of primers for the
ChIP experiments by arrows. (B) Methylated (white bar) or mock-methylated (black bar) human INS promoter constructs were transfected into NIT-1
insulinoma cells 48 hours prior to the luciferase assay. The data were normalized with co-transfected control vector and are the average and standard
error from three separate experiments of eight replicates each. Data are presented as relative expression compared with the non-methylated, non-
stimulated sample. *=p,0.0001 (C) Methylated (white bars) or mock-methylated (black bars) mouse Ins2 promoter constructs were transfected into
NIT-1 insulinoma cells and stimulated for four hours with 2.8 mM glucose (Stimulation -) or with 16.7 mM glucose and 10 mM forskolin (Stimulation
+). The data were scaled to the unmethylated, unstimulated control. The results are the average and standard error from three separate experiments
of eight replicates each. *=p,0.0001 compared with control. (D) The minimal Ins2 promoter construct was treated and analyzed as in 1C. There was
no significant effect of methylation or stimulation on minimal promoter activity (one-way ANOVA p=0.9928). (E) The mouse Ins2 promoter construct
was methylated individually at each CpG site (white bars) or mock-methylated (black bar) and then transfected and analyzed as in 1B. The results are
the average and standard error from three to five experiments of eight replicates each. *=p,0.0001 compared with control.
doi:10.1371/journal.pone.0006953.g002
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1.0060.08 vs. 1.8660.15, p,0.0001). This shows that methyla-
tion-dependent suppression of the insulin promoter is not simply
additive, and that other mechanisms are likely present in the cell
that cooperate with DNA methylation to turn off the insulin gene.
Methylation indirectly inhibits factor binding to the CRE
Suppression of gene expression by methylation of the CpG at
2182 bp suggested that methylation may regulate the binding of
transcription factors to the CRE site. CREB and ATF2 are
reported to bind to the Ins2 CRE site and play an important role in
insulin transcription [26]. Several studies have demonstrated that
CpG methylation of CRE sites suppresses the binding of
transcription factors and represses gene expression [27–29]. To
test the effect of methylation on factors binding to the CRE site,
double stranded 24 bp oligomers of the Ins2 promoter CRE site
were synthesized and methylated in vitro or mock methylated.
Methylation of the oligonucleotides was confirmed by inhibition of
AatII restriction digest (not shown). Electrophoretic mobility shift
assays (EMSA) were carried out using NIT-1 nuclear extracts to
test whether methylation inhibited factor binding to the CRE site.
In contrast to other studies [27,28], we found dose-dependent
binding to the CRE site regardless of the methylation status
(Fig. 3A). To determine if the factors binding to methylated and
unmethylated oligonucleotide were able to be displaced, increasing
concentrations of unlabeled oligonucleotide were allowed to
compete with the labeled oligonucleotides for binding (Fig. 3B).
Both methylated and unmethylated unlabeled oligonucleotides
effectively competed with the labeled probes for factor binding,
indicating that methylation had no effect on factor binding to the
Ins2 CRE in vitro. According to this result, the methylation-
dependent repression of insulin gene expression was not due to
direct inhibition of transcription factor binding.
Alternatively, another protein(s) might bind exclusively to the
methylated CRE site and regulate Ins2 transcription. The methyl-
CpG-binding protein MeCP2 has been reported to bind to
methylated CpG motifs [30] in CRE sites, which may block
binding of other factors. Additionally, the binding of MeCP2 to
methylated DNA sites in gene promoters recruits histone
deacetylases, causing deacetylation of histone protein tails and
chromatin condensation around the gene promoter, resulting in
transcriptional repression [31]. We used chromatin immunopre-
cipitation (ChIP) experiments to determine the factors binding the
CRE in the endogenous Ins2 gene in NIT-1 insulinoma cells. As
shown in Figure 1A, this promoter is completely demethylated,
and both CREB and ATF2, but not MeCP2, were associated with
the endogenous gene as previously reported (Figure 3C) [26].
To investigate the effect of methylation on factor binding in vivo,
ChIP experiments were carried out using methylated or mock
methylated reporter plasmids transfected into NIT-1 cells. Whole
pGL4.10Ins2500bp plasmid was methylated using M.SssI CpG
methyltransferase and methylation status was confirmed by
digestion with the methylation-sensitive enzyme HpaII and
methylation-insensitive enzyme MspI, and it was also confirmed
that DNA methylation did not alter PCR efficiency (data not
shown). To avoid background from the endogenous gene, ChIP
PCR primers were designed to amplify only the transfected
reporter DNA (Fig. 2A). NIT-1 cells were transfected with whole
methylated or unmethylated pGL4.10Ins2500bp, cross-linked with
formaldehyde, and precipitated with specific antibodies against
CREB, ATF2, and MeCP2. The ChIP data shows that CpG
methylation inhibited the binding of CREB and ATF2 to the Ins2
promoter CRE site, but increased the binding of MeCP2 (Fig. 3D).
Therefore, the binding of the CRE-binding proteins in NIT-1 cells
to the insulin promoter is inhibited by methylation inside the cells,
but not in vitro. This implies that MeCP2, and possibly other
methylated CpG binding proteins, are binding to the methylated
promoter and preventing binding of the activators, resulting in a
decrease in insulin gene expression. Similar reciprocal binding of
CREB and MeCP2 has also been reported by another group [28].
Insulin gene is demethylated during differentiation of
insulin-producing cells
Induction of insulin gene transcription occurs rapidly (,30 min)
following glucose stimulation and involves acute changes in
chromatin structure [32]. However, in the present study the insulin
promoter was demethylated in adult insulin-producing cells even
when cells were cultured at normal glucose levels (7 mM for mouse
islets, 5.5 mM for human islets; Fig. 1), implying that methylation
may not be important for acute regulation of insulin gene
Table 1. Primers for bisulfite sequencing, reporter constructs, and ChIP assays.
Primers Position Strand Sequence (59 to 39)
Ins2 bisulfite 2516– 2126 Sense TTTAAGTGGGATATGGAAAGAGAGATA
Antisense ACTACAATTTCCAAACACTTCCCTAATA
Ins2 reporter 2480– +15 Sense GAGCTCGGACCATTAAGTGCCTTGCTGCCT
Antisense AAGCTTGGATCACTTAGGGCTGGTGGTTACTGG
Ins2 minimal 2169– +15 Sense GAGCTCCTTTCTGCAGACCTAGCACCAGG
Antisense AAGCTTGGATCACTTAGGGCTGGTGGTTACTGG
Plasmid ChIP Ins2 2190– luc2 +21 Sense GGTGTTGACGTCCAATGAGCGCTTTCTGCAGA
Antisense CGCTGGGCCCTTCTTAATGTTTTTGGCATCTTCCA
Genomic ChIP 2276– 278 Sense CTGGAACAATGTCCCCTGCTGTGAACTGGTTC
Antisense TTAAGGGCTCCAGGTGGGGTAGGTCAGCAGA
INS bisulfite 2385– +31 Sense TTTGGGGATAGGGGTTTGGGGATAGTA
Antisense CCTCTTCTAATACAACCTATCCTAAAAAACTAAAAACTAC
INS reporter 2385– +24 Sense GAGCTCTGTGGGGACAGGGGTCTGGGGA
Antisense AAGCTTCTGATGCAGCCTGTCCTGGAGGGCTGAGG
doi:10.1371/journal.pone.0006953.t001
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ylation may be a developmentally regulated process involved in the
differentiation of beta cells. This would mean that either the insulin
gene is demethylated in the embryo and becomes preferentially
methylated in all cells butthe beta cells, or the reverse is true, i.e. the
gene is methylated in the embryo and becomes specifically
demethylated in beta cells. To evaluate these possibilities, we
followed the changes in the methylation pattern as mouse
embryonic stem cells differentiated into insulin-expressing cells.
Many groups are trying to generate insulin-producing beta cells
from several types of adult and embryonic cells, however, the
conversion ratio to insulin positivity is very low [20,33]. Our prior
studies had succeeded in enriching for insulin-positive cell clusters
derived from a mouse embryonic stem cell (mESC) line [34] that
has one allele of the neurogenin 3 (Ngn3) gene replaced with
Enhanced Green Fluorescent Protein (EGFP) reporter [35].
During development, Ngn3 marks the proendocrine cells of the
developing pancreas and is required for their differentiation
[36,37], so this method enriches for cells which are already
proceeding down a pathway to hormone expression. In this
method, mESC were allowed to differentiate into embryoid bodies
(EB) for six days in culture, and then the EB were collected,
washed, and cultured in tertiary media for 9 to 11 days. At the end
of tertiary culture, the cells were dissociated and FACS-sorted into
GFP positive (Ngn3-EGFP
+) and negative (Ngn3-EGFP
2) popu-
lations, representing proendocrine and non-endocrine fractions,
respectively. Since the half-life of EGFP transcript is longer than
Ngn3, some of the EGFP+ cells may already proceed down a
pathway to hormone expression. The Ngn3-EGFP
+ population
was induced to further differentiate by 3-dimensional culture in
extracellular matrix, and colonies of differentiated insulin-
expressing cells were handpicked for analysis. Genomic DNA
was isolated from cells at each of the six stages and also from
mouse liver as a negative control and mouse beta cells and NIT-1
cells as positive controls. The DNA methylation pattern of the
insulin promoter in each of these cell populations was determined
by pyrosequencing.
As shown in Figure 4, the insulin gene promoter in mESC is
methylated on all three CpG sites, similar to the liver DNA
control. The methylation status is maintained through embryoid
body formation (Fig. 4; EB) and endodermal differentiation in the
tertiary culture (Fig. 4; FACS presort). Surprisingly, the insulin
promoter in the Ngn3-EGFP
+ proendocrine cell population
(Fig. 4.; FACS (+) sort), which exhibits detectable Ins2 gene
expression [34], was still fully methylated. It was not until the final
stage of in vitro differentiation (Fig. 4; colonies) that there was
significant demethylation of two (2182 and 2414) of the three
CpG sites. This result shows that complete demethylation of the
insulin promoter is a late step in the differentiation of the beta cell
phenotype, and is preceded by low level insulin gene expression. It
should be noted that the level of insulin gene expression, even in
the final stage of in vitro differentiation, is substantially lower than
that of fully differentiated mouse beta cells.
Discussion
The insulin molecule is central to metabolic homeostasis, and as
such insulin activity is regulated at multiple levels. Previous studies
have established the regulation of insulin activity at the transcrip-
tional [21,22,24], post-transcriptional [32], translational [38,39],
secretory [40], and even post-receptor levels [41,42]. In this study
we have demonstrated that human insulin gene and mouse insulin2
gene expression are also controlled epigenetically by methylation of
specific CpG sitesinthe promoterregions. Innon-insulin expressing
Figure 3. Effect of methylation on transcription factor binding
to the Ins2 promoter. (A) Increasing amounts of NIT-1 nuclear extract
was bound to methylated or unmethylated mouse Ins2 promoter CRE
oligonucleotide in an Electrophoretic Mobility Shift Assay (EMSA). There
was a dose-dependent increase in binding to both the methylated and
unmethylated CRE with increasing amounts of NIT-1 cell nuclear extract.
(B) The binding of NIT-1 nuclear proteins to one nanomolar of either
labeled methylated (mCRE) or unmethylated (CRE) was competed with
increasing concentrations of unlabeled CRE or mCRE. The figure is one
representative of four experiments. (C) Chromatin immunoprecipitation
(ChIP) analysis of the endogenous mouse Ins2 gene promoter in NIT-1
cells. Genomic DNA was immunoprecipitated with anti-CREB, anti-ATF2,
anti-MECP2, and control IgG. The results indicate that CREB and ATF2,
but not MeCP2, are normally associated with the endogenous insulin
promoter. (D) Methylated or mock-methylated pGL4.10Ins2500bp
(Fig. 2A) was transfected into NIT-1 cells and then ChIP was carried
out with anti-CREB, anti-ATF2, and anti-MeCP2 antibodies. Methylation
of the Ins2 promoter decreases the binding of CREB and ATF2, but
increases the binding of MeCP2.
doi:10.1371/journal.pone.0006953.g003
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expressing cells they are completely demethylated.
In general, DNA methylation has a suppressive effect on gene
transcription.Weshowthatthisisalsotrueofthehumanand mouse
insulin promoters, where complete methylation suppressed reporter
gene expression by 85% and 79%, respectively (Figs. 2B and 2C).
However, methylation of the individual sites in the mouse promoter
revealed only one site, the CpG at position 2182, which
significantly suppressed gene expression, and only by about 50%.
Paradoxically, methylation of the distal CpG at position 2414
significantly increased gene expression by 86%. Since complete
methylation suppresses insulin promoter activity, these observations
implythatmethylation-dependentcontrolofinsulingene expression
is indirect, probably involving a higher levels of DNA structure such
as nucleotide positioning and chromatin compaction.
The CpG site at position 2182 in the mouse Ins2 promoter is
located within a cyclic-adenosine monophosphate response
element (CRE) which was previously shown to be involved in
insulin gene expression. Previous studies have demonstrated that
CRE methylation suppresses transcription of other genes, usually
by direct inhibition of binding of the transcription factor CREB.
Therefore, we investigated the effect of methylation on binding of
beta cell factors to the CRE sequence in the mouse Ins2 gene. In
agreement with other groups, we found that the transcription
factor ATF2 binds to the insulin promoter CRE and that
overexpression of ATF2 increases insulin gene expression, whereas
CREB overexpression actually suppresses the insulin promoter
(data not shown). We also found that binding of both ATF2 and
CREB to the insulin promoter CRE in vivo was inhibited by
methylation. However, in contrast to other gene promoters, we
found that methylation did not directly inhibit transcription factor
binding to the CRE in the insulin promoter. Importantly,
methylation increased the binding of the methylated DNA binding
protein MeCP2. We believe that the binding of MeCP2 to the
methylated CpG in the CRE site may compete with binding of
other factors, thus contributing to the suppression of gene
expression.
Yet the predominant suppressive effect of binding of MeCP2 to
the insulin gene is probably not due to blocking of transcriptional
activators since methylation of the CRE CpG alone results in only
50% inhibition, but rather MeCP2 binding likely recruits histone
deacetylases that maintain the chromatin in a compacted state.
Wu and Gilbert [43] showed long ago that the promoter of the rat
insulin 2 gene exhibits tissue-specific sensitivity to DNase I,
indicating a relaxed chromatin structure in this region in insulin-
producing cells. More recently the Mirmira laboratory has
provided a mechanism for this observation, showing that there is
a beta cell-specific shift in nucleosome positioning in the insulin
promoter, allowing the binding of the PDX-1 transcription factor
[44], which recruits histone methylase to the promoter [45], thus
stabilizing the open chromatin structure and providing the
opportunity for transcription. We speculate that an initiating
event in this process is the beta cell-specific demethylation of the
insulin locus resulting in the relaxation of the chromatin structure
and repositioning of the nucleosomes.
Therefore, unlike other mechanisms controlling insulin activ-
ity, methylation is likely involved in the development of insulin-
producing cells rather than in daily metabolic regulation. When
one particular developmental model was examined, i.e. the
transition of mouse embryonic stem cells to endodermal-like cells
and then into an early pancreatic lineage in vitro, it appeared that
there is a transition in the insulin promoter from full methylation
to partial demethylation. However, decrease in methylation at
specific sites occurs very late in the differentiation program and
was incomplete in this model, even in the isolated Ngn3-EGFP
+
pancreatic endocrine lineage cells. This indicates that demethyl-
ation is one of the very late steps in differentiation of insulin-
producing cells. This may be one of the reasons that no one has
yet been able to achieve efficient differentiation of functional
insulin-producing cells in vitro. As yet, the precise mechanism of
gene-specific DNA demethylation has not been unraveled. It may
be a passive process involving replication in absence of
maintenance DNA methylation. Alternatively, recent studies
indicate that active DNA demethylation may occur and this
pathway may involve interaction between cytosine deaminase and
thymine-DNA glycosylase [46,47]. The developmental control of
gene-specific DNA demethylation is the subject of ongoing
investigations.
In conclusion, this study demonstrates that DNA methylation
suppresses insulin gene expression and that the insulin gene
promoter is specifically demethylated in insulin-producing cells.
Methylation recruits MeCP2, and possibly other methylated DNA
binding proteins, resulting in decreased binding of the transcrip-
tional activators, ATF2 and CREB. Furthermore, demethylation
of the insulin gene appears to be an important and potentially rate-
limiting step in the differentiation of insulin-producing cells from
embryonic stem cells.
Materials and Methods
Ethics Statement
Animals used in this study received high quality animal care
consistent with the Public Health Service Policy on Humane Care
and Use of Laboratory Animals, the Guide for the Care and Use of
Laboratory Animals, and the Animal Welfare Act. The animal care
facility at the City of Hope has been approved by the National
Institutes of Health, registered with the U.S. Department of
Agriculture, and fully accredited by the Association for Assessment
and Accreditation of Laboratory Animal Care International
Figure 4. Demethylation of the Ins2 promoter during differen-
tiation of mouse embryonic stem cells to insulin-expressing
colonies. Mouse embryonic stem cells from Ngn3-EGFP mice were
induced to differentiate through several stages into insulin-expressing
colonies as previously described [34]. Genomic DNA from each stage
was isolated, bisulfite-treated, and the methylation status was
determined by pyrosequencing. The methylation status of the three
CpG sites is plotted individually: 2171 (white), 2182 (black), 2414
(hatched). The bars represent the averages and standard deviations of
three independent stem cell experiments. Genomic DNA samples from
mouse liver and purified beta cells were processed in parallel with each
experiment as negative and positive controls, respectively. * p,0.05
compared with previous stage.
doi:10.1371/journal.pone.0006953.g004
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number of animals required to obtain valid results.
Mouse islet cell preparations
Pancreata from NODscid or Balb/c mice were digested with
1 mg/ml Liberase (Sigma-Aldrich, St. Louis, MO) for 11 minutes
in 37uC and then purified islets were separated using Histopaque-
1077 (Sigma-Aldrich, St. Louis, MO) followed by hand picking.
Isolated islets were cultured overnight and dissociated using
Accutase (Innovative Cell Technologies, CA) for 8 minutes and
one tenth of the dissociated cells were used for immunocytochem-
istry to determine purity and composition.
Human pancreatic beta cell sorting
Human islet cell isolation at the City of Hope National Medical
Center was performed with the approval of the Institutional
Review Board (IRB# 01083 and 05058). Written informed
consent from the donors for research use of tissue in this study was
obtained prior to acquisition of the organ. Ten thousand Islet
Equivalent (IEQ) human islets from four different donors in
independent experiments were incubated with TrypLE (Invitro-
gen, Carlsbad, CA) at 37uC for 15 min. Dissociated islet cells were
passed through the 100 and 40 micron strainers. The cells were
incubated with 1microM Newport Green (Invitrogen, Carlsbad,
CA) at 37uC for 1 hour. The cells were resuspended with
phosphate buffer containing 0.1% human serum albumin and
2 mM MgCl2. MoFlo High-Performance Cell Sorter (DAKO,
Carpinteria, CA, USA) was used for Newport Green positive cell
sorting. One tenth of the sorted cells were used for immunocy-
tochemistry and genomic DNA was isolated from the remaining
cells. Human non-islet pancreatic tissue containing less than 0.1%
islet cells was obtained following the islet isolation procedure by
the Southern California-Islet Cell Resource center at the City of
Hope.
Immunocytochemistry
Immunocytochemical analyses were performed on cells at-
tached to polylysine-coated coverslips and fixed with 4%
paraformaldehyde, cold methanol and acetone. The following
primary antibodies were used for immunocytochemical staining:
guinea pig anti-insulin (Millipore, St Charles, MO), rabbit anti-
glucagon (Millipore, St Charles, MO). Corresponding secondary
antibodies against each first antibody/immunoglobulin were either
conjugated with fluorescein isothiocyanate (FITC) or Texas red
(Jackson Immuno-Research Laboratories, West Grove, PA).
Stained samples were embedded in Vectashield (Vector Labora-
tories, Burlingame, CA) and examined under an Olympus BX51
fluorescent microscope, equipped with a Pixera 600 CL cooled
CCD camera (Olympus America, Melville, NY). A picture for
each individual color was separately captured using Pixera
Viewfinder 3.0 acquisition software (Pixera, Los Gatos, CA). Cell
percentages were determined by manual counting of at least six
randomly chosen fields.
Cell culture
Mouse beta-cell line NIT-1 cells [18] were purchased from
American Type Culture Collection (Manassas, VA, USA) and
were cultured in Hams F12K media supplemented with 10% fetal
bovine serum and antibiotics. Cells were maintained at 37uCi na
humidified atmosphere containing 95% air and 5% CO2. Cells
were passaged by trypsinization and subcultured on a weekly basis.
Passage 2 or 3 cells were used for all the experiments.
Isolation of genomic DNA
Genomic DNA was obtained from mice liver, spleen, kidney,
brain, muscle, blood, isolated pancreatic islet of NODscid mice or
Balb/c mice using ZR genomic DNA kit (Zymo Research,
Orange, CA). Tissues were obtained from four NODscid mice and
three Balb/c mice for comparing tissue-specific methylation
patterns. We observed no strain-specific differences in methylation
patterns. TRIzol reagent (Molecular Research Center, Cincinnati,
OH, USA) was used for human islet genomic DNA preparation.
Bisulfite genomic sequencing
Nucleotide sequences of the mouse Ins2 gene (GeneID: 16334)
and the human INS (GeneID: 3630) gene were obtained from
Genbank and the potential methylation sites (i.e. CG dinucleo-
tides) were identified. Genomic DNA samples were treated with
EZ DNA methylation kit (Zymo Research, Orange, CA) according
to the manufacturer’s recommendation. The mouse Ins2 gene or
human insulin gene was then amplified with pairs of gene-specific
primers (Table 1) in a mixture containing 100 ng bisulfite-
modified DNA. PCR was done using Hot Star-Taq polymerase
(Qiagen, Valencia, CA). Each PCR fragment was TA cloned into
pCR2.1-TOPO vector (Invitrogen, Carlsbad, CA) and trans-
formed with the TOP10-competent cells (Invitrogen, Carlsbad,
CA). 5–24 clones of each sample were selected and sequenced with
M13F primer or M13R primer. Sequencing was performed by the
DNA Sequencing Lab in the Beckman Institute at the City of
Hope. There were no discernible strain-specific differences in the
tissue-specific methylation patterns between the NODscid and
Balb/c mice.
Construction of reporter gene plasmids
pGL4.10-Basic vector (Promega, Madison, WI) was digested
with SacI/HindIII and treated with alkaline phosphatase (CIP)
(New England BioLabs, Ipswich, MA). Fragments of the mouse
Ins2 promoter (2480– +15 bp containing 3 CpG sites
(pGL4.10Ins2500bp) and 169– +15 bp containing no CpG sites
(pGL4.10Ins2MP) and of the human INS promoter (2385–
+24 bp containing nine CpG sites (pGL4.10INS421bp) were
amplified by PCR using genomic DNA and primers that added
a3 9 SacI site and a 59 HindIII site (Table 1). PCR products were
inserted into pCR2.1 TOPO vector using TA cloning kit and
amplified in ZYM-505 medium [48]. The plasmid sequences were
confirmed by DNA sequencing. The cloned promoter fragments
were excised and subcloned upstream of the firefly luciferase gene
in the pGL4.10-Basic vector (Promega, Madison, WI) using
Fastlink ligation kit (Epicentre, Madison, WI, USA) according to
the manufacturer’s recommendation and transformed into TOP10
competent cells (Invitrogen, Carlsbad, California) for plasmid
production.
In vitro methylation and mock methylation of insulin2 or
human insulin promoter
pCR2.1 plasmids containing the promoter region of Ins2 SacI–
480 to +15 bp-HindIII, SacI–169– +15 bp-HindIII, and the
promoter of human insulin SacI–385 to +24 bp-HindIII were
digested with SacI/HindIII and insert DNA were gel purified and
methylated using M.SssI CpG methyltransferase (New England
Biolabs, Ipswich, MA), which methylates all cytosine residues
within the double-stranded dinucleotide recognition sequence 59-
CG-39. One microgram promoter DNA was methylated using
10 U of M.SssI CpG methyltransferase, or in a parallel control
reaction, mock-methylated in the absence of enzyme. Methylated
and mock-methylated plasmids were religated into SacI/HindIII-
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promoter constructs were identified and gel purified, quantitated
by spectrophotometry, and confirmed by restriction enzyme
digestion prior to transfection. For the Ins2 promoter, the CpG
methylated insert was confirmed by digestion with the methyla-
tion-sensitive restriction enzyme AatII, which recognizes the
GACGTC site at 2184–179 bp of Ins2 promoter. For the INS
promoter, the CpG methylated insert was confirmed with HpaII
and MspI (New England Biolabs, Ipswich, MA). HpaII is a
methylation-sensitive restriction endonuclease that cleaves DNA at
CCGG sequences when the internal cytosine residue is unmethy-
lated on both strands. MspI cleaves DNA regardless of
methylation status of the internal cytosine and serves as a control
for digestion efficiency.
Site specific methylation of the Ins2 promoter
There are 3 CpG sites in the Ins2 proximal promoter at
positions 2414, 2182, and 2171 bp. Site specific methylation of
pGL4.10Ins2500bp was carried out with the QuikChange Site
Directed Mutagenesis Kit using a protocol adapted from
Martinowich et al. [50]. Briefly, methylated primers from
sequences around CpG sites 2414, 2182, and 2171 bp of the
Ins2 promoter were purchased from IDT (Coralville, IA). The
following primers and their reverse complements, containing
methylated CpG, were used: 2414 bp CpG: 59-GAGAGA-
GAGCTGGGGACTCGGCTGAGTTAAGA-39; 2182 and
2171 bp CpGs: 59-CTAAGTAGAGGTGTTGACGTCCAAA-
TGAGCGCTTTCTGCAGAC-39. Control unmethylated vector
was generated using the unmethylated primers for the 2182 and
2171 bp sequences. PCR was carried out according to the
manufacturer’s protocol with 100 ng of pGL4.10Ins2500bp per
reaction. Following the PCR, the reaction was treated with DpnI
for 2 h to remove the template DNA. The product was purified
using DNA clean and concentrater-5 (Zymo Research, Orange,
CA). DNA concentration was quantitated by gel electrophoresis.
Transient transfection and luciferase reporter assays
The unmethylated (mock-methylated), totally methylated, or
point methylated Ins2 promoter/firefly luciferase fusion genes,
pGL4.10Ins2500bp or pGL4.10Ins2MP were transfected in NIT-1
cells using Fugene 6 (Roche, Indianapolis, IN, USA). In each
experiment, the phRL-TK, encoding Renilla luciferase (Promega,
Madison, WI), was cotransfected as normalization control.
Luminescence was measured 48 h after transfection using the
dual-luciferase reporter assay system (Promega, Madison, WI). For
stimulation assays, four hours before the assay the medium was
replaced with 100 ml RPMI and 10% fetal bovine serum with
2.8 mM glucose or 16.7 mM glucose with 10 mM of forskolin.
Reporter activity was normalized by calculating the ratio of firefly
to Renilla values. Each construct was tested in three to five
independent transfections.
Electrophoretic Mobility Shift Assays
Sense and antisense strand oligonucleotides corresponding to
positions 2194 to 2160 of the mouse Ins2 promoter and
containing CRE and two CpG sites (sense: 59-tagaggtgttgaCGtc-
caatgagCGctttctgcag-39; antisense: 59-ctgcagaaagCGctcattggaCG-
tcaacacctcta-39; CpG sites are capitalized, the CRE is underlined)
were synthesized by IDT. The oligonucleotides were labeled with
biotin at the 39-end using the Pierce Biotin 39 End DNA Labeling
Kit (Rockford, IL, USA), then annealed, and an aliquot was
methylated using M.SssI CpG methylase (New England Biolabs,
Ipswich, MA). The methylation status of the oligonucleotide was
confirmed by CpG methylation sensitive restriction digest with
AatII. Nuclear extracts of NIT-1 cells were prepared according to
Schreiber et al [51] with the addition of 1 mM NaF and 0.2 mM
NaVO4, and the protein concentration determined using the
BioRad Protein Assay (Hercules, CA, USA). Methylated or
unmethylated oligonucleotides (20 fmol) were mixed with 2–8 mg
NIT-1 nuclear protein in 20 ml of 15 mM Tris-HCl, 50 mM KCl,
0.1 mM EDTA, 1 mM DTT, 0.1 mg/ml BSA, 10% glycerol,
0.05% NP40, 0.5 mM biotin, and 0.1 mg/ml poly-(dIdC) and
incubated for 30 minutes at room temperature. Binding was
assessed by separation on 6% polyacrylamide/0.5x TBE gels,
transfer to nylon membranes, and detection with LightShift
Chemiluminescent EMSA reagents (Pierce, Rockford, IL, USA).
Transfected plasmid ChIP
pGL4.10Ins2500bp (40 mg) was treated with M.SssI (60 U)
overnight in 37uC. The unmethylated and methylated plasmids
(200 ng) were digested with 20 U of either HpaII or MspI at 37uC
overnight to confirm the methylation status. NIT-1 cells growing
on 3610-cm culture dishes were transfected with 18 mg of whole
CpG methylated or unmethylated pGL4.10Ins2500bp using
Fugene6 transfection reagent. Chromatin immunoprecipitation
(ChIP) was carried out using enzymatic shearing method kit
(Active Motif, Carlsbad, CA, USA) according to the manufactur-
er’s recommendations with the following antibodies: mouse anti-
CREB (Invitrogen, Carlsbad, CA), rabbit polyclonal anti-ATF2
(Santa-Cruz, Santa Cruz, CA, USA), rabbit polyclonal anti-
MeCP2 (Upstate, Chicago, IL, USA). Amplification of the
immunoprecipitated DNA was achieved using Hot Star Taq
DNA polymerase and 5 ml of either immunoprecipitated DNA, or
a 1:10 dilution of input chromatin. Experimental reactions were
performed to determine optimal PCR conditions so that the yield
of PCR products was dependent on the amount of input DNA
(data not shown). The conditions for all reactions were as follows:
94uC for 15 min, followed by 32 cycles at 94uC for 30 seconds,
61uC for 30 seconds, 72uC for 1 min, and 72uC for 10 min.
Primers were designed to amplify only reporter construct DNA
(Fig. 2A and Table 1). PCR products were electrophoresed on 2%
agarose gels and stained with ethidium bromide.
Genomic ChIP
NIT-1 cells growing on 3610-cm culture dishes were used for
genomic ChIP. ChIP was carried out with the same antibodies
utilized in the plasmid ChIP. The normal control rabbit IgG
(Alpha Diagnostic, Carlsbad, CA, USA) was used for the negative
control. The conditions for all reactions were as follows: 94uC for
15 min, followed by 33 cycles at 94uC for 30 seconds, 63uC for 30
seconds, 72uC for 1 min, and 72uC for 10 min.
Pyrosequencing
Mouse embryonic stem cell were differentiated and sorted and
cultured as previously described [34], and genomic DNA from
samples at each stage were isolated and bisulfite converted.
Pyrosequencing of the Ins2 promoter region was done by
EpigenDX (Worcester, MA) using 59-biotinylated primer sets.
Liver and beta cell bisulfite treated genomic DNA PCR were
analyzed simultaneously as negative and positive controls,
respectively. The percentages of methylation at each CpG site in
the Ins2 promoter are shown for each stage of differentiation.
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